Nicole Cotroneo, B.S.

Director
Spero Therapeutics

Disclosure(s): Spero Therapeutics: Employee, Stocks/Bonds

Poster(s):

• 150 - Low Propensity for Development of Spontaneous In Vitro Resistance to Tebipenem, Ertapenem and Meropenem Among Enterobacterales Uropathogens
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1695 - Combination Therapy for the Investigational Polymyxin SPR206 and Meropenem (MEM) Increases the Rapidity and Extent of Killing of Pseudomonas aeruginosa (PA) and Prevents the Bacterium from Emerging Resistant to Both Antibiotics
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET